Travere SVP sells 5,375 shares after option exercise
Travere Therapeutics’ chief accounting officer exercised options for 5,375 TVTX shares and sold an equal number under a pre-arranged Rule 10b5-1 trading plan.
Rhea-AI Filing Summary
Travere Therapeutics, Inc. (TVTX) reported that Sandra Calvin, its SVP, Chief Accounting Officer, exercised employee stock options for a total of 5,375 shares of common stock on September 15, 2026 at strike prices of $27.50, $22.40, and $20.46 per share, and on the same date sold 5,375 shares of common stock in multiple transactions at weighted average prices between about $62.14 and $63.66. The sales were made pursuant to a Rule 10b5-1(c) trading plan adopted on June 16, 2026.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 5,375 shares ($205K approx. pre-tax spread)
Exercise and Sale
9 txns
Insider
Calvin Sandra
Role
SVP, CHIEF ACCOUNTING OFFICER
Sold
5,375 shs ($335K)
Approx. gross sale proceeds
$335K
Approx. exercise cost
$130K
Approx. pre-tax spread
$205K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Employee stock option (right to buy) F5 | 2,500 | $0.00 | $0.00 |
| Exercise | Employee stock option (right to buy) F6 | 1,250 | $0.00 | $0.00 |
| Exercise | Employee stock option (right to buy) F7 | 1,625 | $0.00 | $0.00 |
| Exercise | Common Stock | 2,500 | $27.50 | $69K |
| Exercise | Common Stock | 1,250 | $22.40 | $28K |
| Exercise | Common Stock | 1,625 | $20.46 | $33K |
| Sale | Common Stock F1, F2 | 4,275 | $62.135 | $266K |
| Sale | Common Stock F1, F3 | 800 | $62.8481 | $50K |
| Sale | Common Stock F1, F4 | 300 | $63.6633 | $19K |
Holdings After Transaction:
Employee stock option (right to buy) — 21,625 contracts (Direct);
Common Stock — 42,353 shares (Direct)
Footnotes (7)
- F1. This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.
- F2. The weighted average sale price for the transaction reported was $62.135, and the range of prices were between $61.53 and $62.51. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
- F3. The weighted average sale price for the transaction reported was $62.8481, and the range of prices were between $62.62 and $63.19. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
- F4. The weighted average sale price for the transaction reported was $63.6633, and the range of prices were between $63.64 and $63.71. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
- F5. The stock option is fully vested and exercisable.
- F6. One-fourth of the shares subject to the stock option vested and became exercisable on the first anniversary of January 31, 2023, and the remaining shares vest in 36 equal monthly installments thereafter.
- F7. One-fourth of the shares subject to the stock option vested and become exercisable on the first anniversary of January 31, 2025, and the remaining shares vest in 36 equal monthly installments thereafter.
Key Figures
Shares sold: 5,375 shares
Shares exercised from options: 5,375 shares
Strike price 1: $27.50 per share
+5 more
8 metrics
Shares sold
5,375 shares
Common stock sales by SVP, Chief Accounting Officer on September 15, 2026
Shares exercised from options
5,375 shares
Total employee stock options exercised on September 15, 2026
Strike price 1
$27.50 per share
Employee stock option for 2,500 underlying shares, expiring January 31, 2032
Strike price 2
$22.40 per share
Employee stock option for 1,250 underlying shares, expiring January 31, 2033
Strike price 3
$20.46 per share
Employee stock option for 1,625 underlying shares, expiring January 31, 2035
Weighted average sale price (4,275 shares)
$62.135 per share
Sale of 4,275 common shares with price range between $61.53 and $62.51
Weighted average sale price (800 shares)
$62.8481 per share
Sale of 800 common shares with price range between $62.62 and $63.19
Weighted average sale price (300 shares)
$63.6633 per share
Sale of 300 common shares with price range between $63.64 and $63.71
Key Terms
Rule 10b5-1(c), Employee stock option, weighted average sale price, Exercise or conversion of derivative security, +1 more
5 terms
Rule 10b5-1(c) regulatory
"plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c)"
Rule 10b5-1(c) is an SEC guideline that lets company insiders set up a written, pre-planned schedule to buy or sell their company stock when they are not in possession of material, nonpublic information. For investors, it matters because such plans can reduce the appearance of insider trading by separating decisions from inside knowledge—like putting your trades on autopilot—while also requiring scrutiny since pre-planned trades can still affect market confidence and share value.
Employee stock option financial
"security title is Employee stock option (right to buy) for three transactions"
An employee stock option is a promise that lets a worker buy company shares later at a predetermined price, often after they stay for a certain period or meet performance goals — think of it like a coupon that locks in today's price for a future purchase. It matters to investors because options align employees’ incentives with company performance, can increase the number of shares outstanding (dilution) when exercised, and represent a compensation cost that affects reported profits and shareholder value.
weighted average sale price financial
"The weighted average sale price for the transaction reported was $62.135"
Exercise or conversion of derivative security financial
"transaction code description is Exercise or conversion of derivative security"
vesting financial
"shares subject to the stock option vested and became exercisable on the first anniversary"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Travere Therapeutics (TVTX) disclose for September 15, 2026?
Travere Therapeutics disclosed that its SVP, Chief Accounting Officer, Sandra Calvin, exercised employee stock options for 5,375 shares of common stock and sold 5,375 shares of common stock in multiple transactions on September 15, 2026.
What stock options did the Travere Therapeutics (TVTX) insider exercise?
On September 15, 2026, the insider exercised three employee stock options covering 2,500 shares at $27.50, 1,250 shares at $22.40, and 1,625 shares at $20.46 per share, each option converting into an equal number of Travere Therapeutics common shares.
Were the Travere Therapeutics (TVTX) insider sales made under a Rule 10b5-1 plan?
Yes. The filing states the sales were made pursuant to a written plan adopted on June 16, 2026 meeting the requirements of Rule 10b5-1(c) under the Securities Exchange Act, and the document-level Rule 10b5-1 checkbox is affirmed.
What is the role of the reporting person in Travere Therapeutics (TVTX)?
The reporting person, Sandra Calvin, is identified as an officer of Travere Therapeutics serving as SVP, Chief Accounting Officer, and the reported transactions relate to her directly held equity awards and common stock.
Did the Travere Therapeutics (TVTX) Form 4 report any remaining option vesting details?
Yes. For one option, one-fourth vested on the first anniversary of January 31, 2023 with the remainder vesting in 36 monthly installments; for another, one-fourth vests on the first anniversary of January 31, 2025 with the remainder vesting in 36 monthly installments.
AI-generated analysis. How Rhea-AI works. Not financial advice.
